Vlad Grishkevich

Vlad Grishkevich has a diverse work experience, beginning with a Master of Science from Ben Gurion University of the Negev in 2007. Vlad then went on to pursue a PhD at Technion - Israel Institute of Technology, where they conducted systems biology research in evolutionary developmental biology. In 2013, they became a Postdoctoral Fellow at the California Institute of Technology, where they developed methods for genome-scale functional screens, gene regulation, and genome editing. From 2015 to 2017, they worked as a Senior Research Scientist at ARIAD Pharmaceuticals, Inc., developing immunological assays and TCR activation genetic screens. Vlad then worked as a Senior Scientist at eGenesis, Inc. from 2017 to 2018, before becoming an Associate Director at Celsius Therapeutics in 2018. In 2021, they moved to Flagship Pioneering as an Associate Director, and is currently working at ProFound Therapeutics as an Associate Director since 2022.

Vlad Grishkevich began their education in 2001 when they attended Belarusian State University. In 2007, they earned an MS in biotechnology and molecular biology from Ben-Gurion University of the Negev. Vlad then went on to pursue a Doctor of Philosophy (PhD) in Systems Biology and Genomics from Technion - Israel Institute of Technology, which they completed in 2013.